This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
Magnolia bark contains two primary active compounds, magnolol and honokiol, which act on the central nervous system by modulating GABA-A receptors. This is the same neurotransmitter system targeted by benzodiazepine medications. Research suggests these compounds promote relaxation and reduce anxiety by enhancing GABA activity without causing significant sedation at typical doses. Evidence Level C supports these anxiolytic effects. In Traditional Chinese Medicine, magnolia bark is classified as a qi-moving herb that calms the spirit while addressing underlying stagnation patterns that contribute to restlessness and tension.
Does magnolia bark interact with any medications?
Yes, magnolia bark may interact with several medication classes. Due to its GABA-modulating effects, it can potentiate central nervous system depressants including benzodiazepines, barbiturates, and alcohol, potentially causing excessive drowsiness or respiratory depression. Magnolia bark may also interact with anticoagulant and antiplatelet medications, as some compounds can affect blood clotting. Additionally, honokiol and magnolol may influence liver enzyme activity, potentially altering the metabolism of various pharmaceuticals. Patients taking prescription medications should consult a qualified healthcare provider before using magnolia bark supplements to assess potential interactions.
What is the recommended dosage for magnolia bark?
Traditional Chinese Medicine practitioners typically prescribe 3-9 grams of dried magnolia bark daily, prepared as a decoction. For standardized extracts, common dosages range from 200-500mg daily, depending on the concentration of active compounds like magnolol and honokiol. Dosage varies based on the specific condition being treated, preparation method, and individual factors. Magnolia bark is often combined with other herbs in traditional formulas rather than used alone. Always follow guidance from a qualified herbalist or healthcare provider, as improper dosing may increase the risk of adverse effects.
Is magnolia bark safe during pregnancy?
No, magnolia bark is contraindicated during pregnancy and should be avoided. In Traditional Chinese Medicine, magnolia bark is classified as a strong qi-moving herb that directs energy downward, which can potentially disrupt pregnancy. The active compounds magnolol and honokiol may stimulate uterine contractions, posing a risk of miscarriage or premature labor. Women who are pregnant, attempting to conceive, or breastfeeding should not use magnolia bark preparations. Individuals with qi deficiency patterns should also use caution, as this herb's strong moving properties may further deplete vital energy.
What is magnolia bark used for in Chinese medicine?
In Traditional Chinese Medicine, magnolia bark (Hou Po) is primarily used to move stagnant qi, dry dampness, and direct rebellious qi downward. It treats digestive complaints including abdominal distension, bloating, and poor appetite. The herb also addresses phlegm obstruction in the respiratory system and is used for coughs with copious phlegm. Additionally, magnolia bark calms the spirit and treats anxiety, insomnia, and restlessness. Evidence Level C supports its traditional use for anxiety and digestive complaints. Practitioners often combine it with other herbs like ginger or pinellia for synergistic effects.
What are the side effects of magnolia bark?
Magnolia bark is generally well-tolerated at recommended doses, but some individuals may experience side effects. Common adverse effects include gastrointestinal upset, mild nausea, and digestive discomfort. Due to its calming properties, some users report drowsiness, dizziness, or fatigue, particularly at higher doses. These effects are typically dose-dependent and reversible upon discontinuation. Long-term use without professional guidance is not recommended. Individuals with existing qi deficiency should use caution, as magnolia bark's strong moving properties may exacerbate underlying weakness. Discontinue use if adverse reactions occur and consult a healthcare provider.
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Magnolia officinalis (Houpo) is a traditional herbal medicine used in Asian countries for its wide range of pharmacological activities, including anti-inflammatory, antioxidant, and neuroprotective effects [PMID:28271656, PMID:34400262].
Background
Magnolia officinalis (Houpo) is a member of the Magnoliaceae family, with the dried bark from its stems, roots, and branches serving as the primary medicinal part [PMID:42057259]. It is widely distributed across China and is a key ingredient in over 200 types of Chinese clinical formulae [PMID:31602929].
Traditional uses
Traditionally used in Chinese and Japanese medicines to treat anxiety, asthma, depression, gastrointestinal disorders, headache, abdominal distention, vomiting, diarrhea, food accumulation, Qi stagnation, constipation, phlegm and fluid retention, and cough [PMID:28271656, PMID:30818008]. It is also used to resolve dampness, eliminate phlegm, promote qi circulation, and treat blood stasis [PMID:42057259, PMID:42108190].
Active compounds
The main active ingredients are neolignans, specifically honokiol and magnolol [PMID:28955265, PMID:29925102]. Other identified constituents include 4-O-methylhonokiol, obovatol, magnoloside A, magnoloside B, magnoflorine, and β-eudesmol [PMID:38955265, PMID:31602929].
Mechanism of action
Mechanisms include activation of the Nrf2 pathway to protect against oxidative stress [PMID:27721050], modulation of NF-κB/MAPK and PI3K/Akt pathways [PMID:31240205], and regulation of autophagy [PMID:26999089]. In cancer cells, magnolol may induce oxeiptosis by promoting reactive oxygen species (ROS) production and impairing mitochondrial-peroxisome interactions [PMID:40347844].
Clinical evidence
Evidence ADepression
Banxia-Houpo-Tang (BHT) alone showed efficacy similar to antidepressants alone in improving Hamilton depression scale (HAMD) scores, while a combination of BHT and antidepressants led to more significant improvement [PMID:37224584].
Evidence DColorectal Cancer
A combination of honokiol, magnolol, and baicalin (HMB) significantly outperformed mono- or bi-agent treatments in reducing tumor growth and was comparable in efficacy to the FOLFIRI regimen [PMID:39950759].
Evidence AAlzheimer's Disease
Neolignans (honokiol, magnolol, 4-O-methylhonokiol, and obovatol) alleviated behavioral abnormalities, learning and cognitive impairments in animal models by inhibiting Aβ generation/aggregation and neuroinflammation [PMID:38955265].
Evidence DNeuropathic Pain
Honokiol-rich standardized extract of M. officinalis bark produced an antiallodynic effect in SNI mice and reduced spinal neuroinflammation markers [PMID:37627513].
Evidence DAtopic Dermatitis
Honokiol administration significantly suppressed mast cell accumulation, inflammation, and serum immunoglobulin E levels in DNCB-induced mouse models [PMID:35074454].
Safety & adverse effects
In vitro and in vivo toxicity studies have been published, though specific human side effects after oral intake are reviewed in literature [PMID:28271656, PMID:29925102]. There is a potential for misuse by individuals seeking natural sedatives due to the GABA-ergic and cannabimimetic activities of magnolol and honokiol [PMID:28517911].
Evidence summary
Evidence is strongest for the use of Magnolia officinalis in combination formulas for depression (meta-analysis) and the neuroprotective effects of its neolignans (systematic reviews). Most other findings are based on in vitro or animal models (D), with limited human clinical trials [PMID:28271656, PMID:37224584, PMID:38955265].
PubMed sources
1.PMID: 39950759 (2025) — Honokiol-Magnolol-Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti-PD-1 Immunotherapy in Colorectal Cancer by Triggering GSDME-Dependent Pyroptosis. · Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2.PMID: 36738944 (2023) — Huanglian-Houpo extract attenuates DSS-induced UC mice by protecting intestinal mucosal barrier and regulating macrophage polarization. · Journal of ethnopharmacology
3.PMID: 28271656 (2017) — Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. · Journal of Zhejiang University. Science. B
4.PMID: 39372674 (2024) — A Comprehensive Review of Coptidis Rhizoma and Magnoliae Officinalis Cortex Drug Pair and Their Chemical Composition, Pharmacological Effects and Pharmacokinetics Analysis. · Drug design, development and therapy
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
— Magnolia officinalis (Hou Po) bark extract stimulates the Nrf2-pathway in hepatocytes and protects against oxidative stress.
· Journal of ethnopharmacology
6.PMID: 38955265 (2024) — Neolignans in Magnolia officinalis as natural anti-Alzheimer's disease agents: A systematic review. · Ageing research reviews
7.PMID: 28517911 (2017) — Is there a potential of misuse for Magnolia officinalis compounds/metabolites? · Human psychopharmacology
8.PMID: 31240205 (2019) — Insights on the Multifunctional Activities of Magnolol. · BioMed research international
9.PMID: 29925102 (2018) — Safety and Toxicology of Magnolol and Honokiol. · Planta medica
10.PMID: 35726011 (2022) — The application prospects of honokiol in dermatology. · Dermatologic therapy
11.PMID: 31602929 (2019) — [Geo-herbalism study of Magnoliae Officinalis Cortex]. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
12.PMID: 42057259 (2026) — Active Constituents of Magnolia officinalis in Cancer Management: Molecular Mechanisms and Therapeutic Potential. · The American journal of Chinese medicine
13.PMID: 36936845 (2023) — Total synthesis of bi-magnolignan. · RSC advances
14.PMID: 41702466 (2026) — Zhi-Zi-Hou-Po decoction ameliorates depressive-like behaviors via TFAM-induced mitophagy in neurons to alleviate neuroinflammation. · Journal of ethnopharmacology
15.PMID: 30818008 (2019) — A review of the phytochemistry and pharmacological activities of Magnoliae officinalis cortex. · Journal of ethnopharmacology
17.PMID: 36879409 (2023) — Magnolia officinalis L. bark extract and respiratory diseases: From traditional Chinese medicine to western medicine via network target. · Phytotherapy research : PTR
18.PMID: 37224584 (2023) — Efficacy and safety of Banxia-Houpo-Tang (Banha-Hubak-Tang) for depression: A systematic review and meta-analysis. · Complementary therapies in clinical practice
19.PMID: 35074454 (2022) — Honokiol suppresses 2,6-dinitrochlorobenzene-induced atopic dermatitis in mice. · Journal of ethnopharmacology
20.PMID: 41391522 (2026) — Banxia Houpo Decoction reduces lysosomal leakage of prefrontal astrocytes through the OGT-CTSB-NLRP3 pathway to improve depressive-like behaviors. · Journal of ethnopharmacology
21.PMID: 26999089 (2016) — New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy. · Molecules (Basel, Switzerland)
22.PMID: 40347844 (2025) — Magnolol facilitates mitochondrial-peroxisome dysfunction and induces oxeiptosis in lung cancer cells following transfer via tunneling nanotubes. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
23.PMID: 33953850 (2021) — Alzheimer's disease treatment: The share of herbal medicines. · Iranian journal of basic medical sciences
24.PMID: 34400262 (2021) — The rich pharmacological activities of Magnolia officinalis and secondary effects based on significant intestinal contributions. · Journal of ethnopharmacology
25.PMID: 42108190 (2026) — [The therapeutic effect of magnolia officinalis on blood stasis in Sheng Nong's Herbal Classic]. · Zhonghua yi shi za zhi (Beijing, China : 1980)
26.PMID: 35784755 (2022) — Neuroprotective Potency of Neolignans in Magnolia officinalis Cortex Against Brain Disorders. · Frontiers in pharmacology
27.PMID: 18855636 (2008) — Medicinal agents in the metabolic syndrome. · Cardiovascular & hematological agents in medicinal chemistry
28.PMID: 40362616 (2025) — The Cardioprotective Effect of Magnolia officinalis and Its Major Bioactive Chemical Constituents. · International journal of molecular sciences
29.PMID: 41435607 (2026) — The antitumor mechanisms of Huangqin Houpo decoction and its effect on chemotherapy-induced toxicity in colorectal cancer. · Phytomedicine : international journal of phytotherapy and phytopharmacology
30.PMID: 35196977 (2023) — The Neuropharmacological Effects of Magnolol and Honokiol: A Review of Signal Pathways and Molecular Mechanisms. · Current molecular pharmacology